Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies

被引:39
作者
Schmieder, Roland E. [1 ]
Schutte, Rudolph [2 ]
Schumacher, Helmut [3 ]
Boehm, Michael [4 ]
Mancia, Giuseppe [5 ]
Weber, Michael A. [6 ]
McQueen, Matthew [7 ]
Teo, Koon [7 ]
Yusuf, Salim [7 ]
机构
[1] Univ Erlangen Nurnberg, Univ Hosp, Dept Hypertens & Nephrol, D-91054 Erlangen, Germany
[2] North West Univ, Hypertens Africa Res Team, Potchefstroom, South Africa
[3] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[4] Univ Saarlandes UKS, Med Fak Univ Saarlandes, Homburg, Germany
[5] Univ Milan Bicoca, S Gerardo Hosp, Clin Med, Monza, Italy
[6] State Univ New York Downstate, Coll Med, Div Cardiol, Brooklyn, NY USA
[7] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
关键词
Albuminuria; Cardiovascular disease; Change; Prognosis; GLOMERULAR-FILTRATION-RATE; HIGH-RISK PATIENTS; CARDIOVASCULAR EVENTS; INDEPENDENT PREDICTOR; ONGOING TELMISARTAN; RENAL OUTCOMES; HEART-DISEASE; URINE SAMPLES; ALL-CAUSE; MICROALBUMINURIA;
D O I
10.1007/s00125-014-3330-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis Urinary albumin excretion is a strong predictor of cardiovascular disease. It is uncertain whether improvement from microalbuminuria or deterioration from normoalbuminuria over time in patients with differing changes in glucose and BP change their cardiovascular risk. Methods Data on mortality, cardiovascular and renal outcomes were analysed in 22,984 patients from two large parallel randomised clinical trials followed for 56 months. A central laboratory analysed first morning spot urine samples at baseline and after 24 months, and events were recorded over the subsequent 32 months. Patients were stratified by changes in albuminuria, glucose status and mean systolic BP over 2 years. Results There was a strong association between albuminuria status and all-cause and cardiovascular mortality and combined cardiovascular and renal endpoints (all p<0.0001). Changes in systolic BP control had no effect on mortality, whereas glucose status was significantly associated with all outcomes. Irrespective of BP control or glucose status, patients showing an improvement from microalbuminuria to normoalbuminuria after 2 years were at a lower risk of all outcome measures than patients showing deterioration from normoalbuminuria to microalbuminuria (HR for all-cause mortality 0.65 [0.52-0.83], p=0.0004). Conclusions/interpretation Patients who showed improvement to normoalbuminuria over 2 years were at lower risk of all-cause and cardiovascular mortality and of cardiovascular and renal events than those who deteriorated to microalbuminuria over time. Albuminuria over time was significantly better than glucose status and BP control in predicting mortality and both cardiovascular and renal outcomes in patients at a high cardiovascular risk.
引用
收藏
页码:2019 / 2029
页数:11
相关论文
共 44 条
[31]   Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms [J].
Stehouwer, Coen D. A. ;
Smulders, Yvo M. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (08) :2106-2111
[32]   Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals [J].
Targher, G. ;
Zoppini, G. ;
Chonchol, M. ;
Negri, C. ;
Stoico, V. ;
Perrone, F. ;
Muggeo, M. ;
Bonora, E. .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2011, 21 (04) :294-301
[34]   Albuminuria as a Risk Factor for Peripheral Arterial Disease in a General Population-The Hisayama Study [J].
Usui, Tomoko ;
Ninomiya, Toshiharu ;
Nagata, Masaharu ;
Doi, Yasufumi ;
Hata, Jun ;
Fukuhara, Masayo ;
Kiyohara, Yutaka .
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2011, 18 (08) :705-712
[35]   Prediction of cardiovascular events, diabetic nephropathy, and mortality by albumin concentration in a spot urine sample in patients with type 2 diabetes [J].
Viana, Luciana Vercoza ;
Gross, Jorge Luiz ;
Camargo, Joiza Lins ;
Zelmanovitz, Themis ;
da Costa Rocha, Enio P. C. ;
Azevedo, Mirela Jobim .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2012, 26 (05) :407-412
[36]   Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus - A blood pressure-independent effect [J].
Viberti, G ;
Wheeldon, NM .
CIRCULATION, 2002, 106 (06) :672-678
[37]   Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease [J].
Vlek, A. L. M. ;
van der Graaf, Y. ;
Spiering, W. ;
Algra, A. ;
Visseren, F. L. J. .
JOURNAL OF INTERNAL MEDICINE, 2008, 264 (04) :351-360
[38]   LIKELIHOOD RATIO TESTS FOR MODEL SELECTION AND NON-NESTED HYPOTHESES [J].
VUONG, QH .
ECONOMETRICA, 1989, 57 (02) :307-333
[39]   IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030 [J].
Whiting, David R. ;
Guariguata, Leonor ;
Weil, Clara ;
Shaw, Jonathan .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 94 (03) :311-321
[40]   Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial [J].
Yusuf, S. ;
Teo, K. ;
Anderson, C. ;
Pogue, J. ;
Dyal, L. ;
Copland, I. ;
Schumacher, H. ;
Dagenais, G. ;
Sleight, P. .
LANCET, 2008, 372 (9644) :1174-1183